Adriamycin is an aminoglycoside antibiotic that has potent antitumour activity in man. Although traditionally classified as a DNA intercalator, it can also interact with the plasma membrane of tumour cells (Tritton & Hickman, 1985) and there is evidence to suggest that these membrane interactions may contribute to its mechanism of action (Tritton & Yee, 1982) . It is not clear how an antiproliferative agent may exert its effect via the plasma membrane. As a model of the interaction between Adriamycin and the plasma membrane, we have studied the effect of the drug on human erythrocytes.
Currently, there is considerable interest in the mechanism whereby changes in erythrocyte morphology are controlled. The erythrocyte is converted from the discocyte to echinocyte form whether either ATP is depleted or calcium is introduced into the cell. We have found Adriamycin to be a potent inhibitor of this morphological transition under either condition (Chahwala & Hickman, 1985) . Recent findAbbreviation used SDS PAGE, SDS polyacrylamide gel electrophore\i\ ings suggest that the maintenance of phosphatidylinositol 4,5-bisphosphate levels in the inner leaflet of the membrane may be necessary for the retention of discocyte morphology (Ferrell & Heustis, 1984; Anderson & Marchesi 1985; Thompson & Hickman 1986) . However, cytoskeletal proteins may also play an important role in determining red-cell shape. The presence of intact ankyrin (band 2.1) in the cytoskeleton has been reported to be a crucial element in the retention of discocyte morphology (Jinbu et al., 1982) . In view of this finding, we have investigated what changes occur in this and other cytoskeletal proteins when erythrocytes treated with Adriamycin, are made to undergo echinocytosis.
When human erythrocytes (10' cells/ml) were treated with Ca" ( 0 -4 0 0~~) for 5min at 37°C in the presence of 5pM-calcium ionophore, A23 187, echinocytosis took place in a concentration-dependent manner. When human erythrocytes were pre-incubated with the antitumour drug Adriamycin (10 PM) for 10 min before Ca'+ addition, Adriamycin was found to exert a potent protective effect against echinocytosis at Ca'+ concentrations up to 1 . 5 0~~. However, Adriamycin was found to lose its protective effect at Ca" concentrations of 200 pM or higher.
SDS-PAGE of the isolated erythrocyte membranes revealed a Ca2+ -concentration-dependent appearance of band 2.3 (the major proteolytic product of ankyrin) and formation of high molecular weight protein cross-linked Human erythrocyte suspensions ( lO7cells/ml) were loaded with 0-400p~-Ca' ' for 5 min at 37°C. The isolated membranes were electrophoresed on a 7.5% acrylamide gel. The stained band 2.3 (arrow) indicates the proteolytic breakdown of ankyrin in response to Ca" (lanes 1 8) and i t s protection by adriamycin (lanes 9-16).
622nd MEETING, LEICESTER aggregates (see Fig. I ). No other major change was observed.
Isolated membranes from Adriamycin-treated erythrocytes showed that the appearance of band 2.3 in response to Ca2+ loading was greatly reduced. This inhibition of ankyrin breakdown was observed up to 400 p~-C a ?
+ . This demonstrated that protection by Adriamycin against proteolytic degradation of ankyrin took place in erythrocytes treated with high Ca'+ (200 4 0 0~~) in which the drug did not prevent the morphological transition.
The results from this study demonstrate a close correlation between the morphological transition and proteolysis of ankyrin at Ca'+ concentrations up to 1 5 0~~. However, at high Ca'+ ( > 2 0 0~~) inhibition of ankyrin breakdown did not correlate with protection against echinocytosis, raising the question whether changes in ankyrin were responsible for the modulation of erythrocyte cell shape under these conditions. The possibility that erythrocyte morphology may be controlled by a mechanism independent of changes in ankyrin has been suggested from work with isolated 'triton-shells' (Branton et al., 1981) .
However, ankyrin breakdown may be a n important step in controlling erythrocyte shape change a t low Ca2+ concentrations ( < 1 5 0~~) ) .
Alternatively, ankyrin changes upon Ca'+ treatment may not be important, but simply reflect the activation of the Ca2+ -dependent protease, calpain, which may modify important cytoskeletal components involved in the shape transition. These possibilities are under further investigation. Although traditionally classified as a D N A intercalator, the antitumour agent Adriamycin can also interact with the plasma membrane of tumour cells (Tritton & Hickman, 1985) . There is evidence to suggest that these membrane interactions may contribute to its mechanism of action (Tritton & Yee. 1982), but how an antiproliferative agent might exert its effect at the level of the plasma membrane is not yet clear. As a model, we have used the erythrocyte to study the interaction between Adriamycin and the plasma membrane. Erythrocytes are converted from the discocyte to echinocyte form when either A T P is depleted or calcium is introduced into the cell. We have found Adriamycin to be a potent inhibitor of this morphological transition under either condition (Chahwala & Hickman, 1985) . Recent findings suggest that maintenance of phosphatidylinositol 4,5-bisphosphate levels in the inner leaflet of the membrane may be necessary for the retention of discocyte morphology (Ferrell & Heustis. 1984; Anderson & Marchesi 1985; Thompson & Hickman, 1986) . However, in addition to the phosphorylation of lipids, phosphorylation of cytoskeletal proteins may also play a n important role in the control of cell shape. In view of this possibility, we have investigated the phosphorylation pattern of cytoskeletal proteins in erythrocytes undergoing the morphological transition in the presence and absence of Adriamycin.
When human erythrocytes ( 107cells/ml) were treated with Ca'+ (0 400 p~) for 5 min at 37°C in the presence of 5 p~-calcium ionophore, A23 187, echinocytosis took place in a concentration-dependent manner. When human erthrocytes were pre-incubated with the antitumour drug Adriamycin Abbreviation used: SDS PAGE; SDS polyacrylamide gel electrophorisis.
( I O~M ) for 10min before Ca'+ addition. Adriamycin was found to exert a potent protective effect against echinocytosis at calcium concentrations of 0 -1 5 0~~. However, Adriamycin was found to lose its protective effect completely at Ca" concentrations of 200pM or higher.
Intact human erythrocytes were metabolically labelled with "P) for 3 h. SDS-PAGE analysis of the isolated membranes indicated the labelling of a t least 17 membrane proteins in a Ca" -concentration-dependent manner. These included bands 2.1, 2.3, 2.4-2.6, p120, band 3, band 4.1. p65, p61, p59, p.53. band 4.9, p43 (actin?), band 6, band 7 and band 8 (see Fig.1 ). Phosphorylation of some of these proteins has been documented and tyrosine phosphorylation is thought to be involved (Boivin & Galand, 1986) . It is possible that increased phosphorylation of cytoskeletal proteins by Ca" could be accounted for by the activation of various protein kinases such as protein kinase C or a calcium-dependent phosphorylating system such as calmodulin-dependent protein kinase. In addition, a phosphoprotein with molecular mass 43 kDa was also observed which coincided with the major cytoskeletal protein band 5 (actin). However, n o phosphorylated form of actin has been reported previously and the true identity of this phosphoprotein has to be examined.
When human erythrocytes were pre-incubated with Adriamycin (5 and I O~M ) , there was a general decrease in the basal phosphorylation of most of the major phosphoproteins in a concentration-dependent manner. Despite the decrease in basal phosphorylation in the presence of Adriamycin, changes in protein phosphorylation occurred as in the controls when the cells were treated with Calf (see Fig. I ). It has been suggested that Adriamycin is capable of inhibiting protein kinase C and calmodulin-dependent protein kinase directly (Katoh et ul., 1981) . However, the concentration of Adriamycin employed was much higher than the cytotoxic dose of Adriamycin. The direct effect of Adriamycin on protein kinase C and calmodulin-dependent protein kinase has to be reinvestigated.
The possibility that the morphological change upon Ca" -treatment was caused by a decrease in intracellular
